Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma.
Administration, Inhalation
Animals
Asthma
/ immunology
Extracellular Matrix
/ metabolism
Horse Diseases
/ immunology
Horses
Immunization
Matrix Metalloproteinase 2
/ metabolism
Matrix Metalloproteinase 9
/ metabolism
Matrix Metalloproteinase Inhibitors
/ pharmacology
Metalloproteases
/ metabolism
Oligodeoxyribonucleotides
/ administration & dosage
Tissue Inhibitor of Metalloproteinase-1
/ antagonists & inhibitors
Tissue Inhibitor of Metalloproteinase-2
/ antagonists & inhibitors
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
01
2019
revised:
04
04
2019
accepted:
02
05
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Inhalation of immunostimulatory bacterial DNA segments (cytosine-phosphate-guanosine-oligodeoxynucleotides, CpG-ODN) normalizes clinical and cytologic parameters in severe equine asthma. We hypothesized that CpG-ODN inhalation also reduces the misbalance of elastinolytic activity in asthmatic horses. Twenty asthmatic horses diagnosed by clinical examinations using a scoring system were included. All horses inhaled CpG-ODNs for 14 days in 2-day intervals. Matrix metalloproteinase (MMP-2/-9) and tissue inhibitors of metalloproteinase (TIMP-1/-2) concentrations were measured in tracheal aspirates using equine sandwich ELISAs before and 2 and 6 weeks after CpG-ODN inhalation. MMP and TIMP concentrations correlated with the results of clinical scoring in all stages of equine asthma. Inhalation therapy led to significant reductions in clinical scores. MMP-2, MMP-9, and TIMP-2 concentrations were significantly reduced immediately, and all MMP and TIMP concentrations 6 weeks after therapy. In equine asthma, overexpression of MMPs contributes to pathological tissue destruction, while TIMPs counteract MMPs with overexpression leading to fibrosis formation. The results of this study show that CpG-ODN inhalation may be an effective therapy to address a misbalance in equine asthma. Misbalance of elastinolytic activity seems to improve by CpG-ODN inhalation for at least 6 weeks posttherapy, which may reduce the remodeling of the extracellular matrix. Further studies should evaluate this effect in comparison to glucocorticoid inhalation therapy. CpG-ODN inhalation may be an effective therapy in the prevention of pulmonary fibrosis formation in equine asthma.
Identifiants
pubmed: 31316303
doi: 10.1155/2019/7845623
pmc: PMC6604421
doi:
Substances chimiques
CPG-oligonucleotide
0
Matrix Metalloproteinase Inhibitors
0
Oligodeoxyribonucleotides
0
Tissue Inhibitor of Metalloproteinase-1
0
Tissue Inhibitor of Metalloproteinase-2
127497-59-0
Metalloproteases
EC 3.4.-
Matrix Metalloproteinase 2
EC 3.4.24.24
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Clinical Trial, Veterinary
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7845623Références
J Allergy Clin Immunol. 1999 Nov;104(5):1015-23
pubmed: 10550747
Int Arch Allergy Immunol. 2000 Nov;123(3):259-67
pubmed: 11112863
Equine Vet J. 2001 Mar;33(2):128-36
pubmed: 11266061
Am J Vet Res. 2001 Jul;62(7):1142-8
pubmed: 11453493
J Asthma. 2001 Sep;38(6):477-84
pubmed: 11642414
Clin Exp Allergy. 2001 Oct;31(10):1623-30
pubmed: 11678864
Annu Rev Immunol. 2002;20:709-60
pubmed: 11861616
Equine Vet J. 2002 Mar;34(2):150-5
pubmed: 11902757
Chest. 2002 Nov;122(5):1543-52
pubmed: 12426251
Int Arch Allergy Immunol. 2002 Nov;129(3):198-203
pubmed: 12444316
Equine Vet J. 2005 Mar;37(2):155-60
pubmed: 15779629
Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):177-81
pubmed: 15853739
Curr Opin Pharmacol. 2005 Jun;5(3):257-63
pubmed: 15907912
Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:137-44
pubmed: 15962113
Equine Vet J. 2005 Sep;37(5):412-7
pubmed: 16163942
Eur J Pharmacol. 2006 Mar 8;533(1-3):133-44
pubmed: 16487964
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
pubmed: 16763660
Vet J. 2010 Jan;183(1):27-38
pubmed: 19022687
Clin Exp Allergy. 2009 Apr;39(4):562-70
pubmed: 19226280
Respir Med. 2009 Nov;103(11):1755-63
pubmed: 19375904
Biochim Biophys Acta. 2010 Jan;1803(1):55-71
pubmed: 20080133
Semin Cancer Biol. 2010 Jun;20(3):161-8
pubmed: 20470890
Vet Immunol Immunopathol. 2011 Nov 15;144(1-2):79-87
pubmed: 21831455
Pharm Res. 2012 Jun;29(6):1650-7
pubmed: 22302522
J Microencapsul. 2012;29(7):615-25
pubmed: 22432849
PLoS One. 2013;8(2):e56352
pubmed: 23441181
Equine Vet J. 2014 May;46(3):276-88
pubmed: 24164473
Mol Immunol. 2015 Jul;66(1):97-105
pubmed: 25547716
J Vet Intern Med. 2015 Jan;29(1):286-93
pubmed: 25619520
Mediators Inflamm. 2015;2015:569512
pubmed: 26770019
Equine Vet J. 2016 Jul;48(4):403-5
pubmed: 27292020
BMC Vet Res. 2016 Dec 9;12(1):282
pubmed: 27938355
Am J Vet Res. 2017 Feb;78(2):244-250
pubmed: 28140635
Immun Inflamm Dis. 2018 Mar;6(1):81-96
pubmed: 29094511
Acta Vet Scand. 1997;38(1):9-16
pubmed: 9129342
Acta Vet Scand. 1997;38(1):17-27
pubmed: 9129343
Am J Respir Crit Care Med. 1998 Dec;158(6):1945-50
pubmed: 9847290